TScan Therapeutics: Finding Their Footing After An Eventful ASH Meeting
Portfolio Pulse from
TScan Therapeutics is advancing in engineered T cell receptor therapies, with promising phase 1 results for TSC-101 targeting HA-2 in acute leukemia. Despite potential GvHD risks, TCRX's strong financials and undervaluation present an opportunity amid biotech pessimism.
February 10, 2025 | 8:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TScan Therapeutics' TSC-101 shows promising phase 1 results for acute leukemia, but potential GvHD risks exist. The company has strong financials with $133.1 million in cash, funding operations into Q4 2026. TCRX stock is undervalued, trading at less than half its Q3 assets.
TScan Therapeutics' promising phase 1 results for TSC-101 in acute leukemia could boost investor confidence. Despite potential GvHD risks, the company's strong financial position and undervaluation make TCRX an attractive investment opportunity, especially in a pessimistic biotech market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100